Triple therapy for hepatitis C virus (HCV) infection: Eligibility, safety and efficacy in a real world setting
B Maasoumy, K Port, AA Markova, B Calle Serrano, L Sollik, J Kirschner, C Mix, MP Manns, H Wedemeyer, M Cornberg · Zeitschrift für Gastroenterologie · 2013 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background:HCV protease inhibitors (PIs) Boceprevir and Telaprevir in combination with PEG-Interferon alfa and Ribavirin (P/R) is the new standard of care in the treatment of chronic HCV genotype 1 (GT1) infection. However, not every HCV GT1 infected patient is eligible for P/R/PI. Furthermore phase III studies did not necessarily reflect real world as patients with advanced liver disease or comorbidities were underrepresented. The aim of our study was to analyze the eligibility, safety and efficacy of P/R/PI for the treatment of chronic HCV GT1 infection in a real world setting of a tertiary referral center. Me…
